Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Lung Cancer

Free Subscription 11.03.2024 3 AJR Am J Roentgenol 1 Am J Ind Med 3 Ann Surg Oncol 1 Anticancer Res 5 BMC Cancer 2 Br J Cancer 1 Cancer Lett 1 Cancer Res 2 Cancer Sci 3 Clin Lung Cancer 6 Clin Nucl Med 2 Eur J Cardiothorac Surg 1 Eur Respir J 1 Int J Radiat Oncol Biol Phys 1 J Cancer Res Clin Oncol 1 J Clin Invest 3 J Nucl Med 1 J Surg Oncol 1 J Thorac Cardiovasc Surg 4 J Thorac Oncol 2 JAMA Oncol 1 Lancet 13 Lung Cancer 1 Mol Cancer Ther 2 Oncogene 1 Oncologist 2 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. PARK C, Lee BC, Jeong WG, Park WJ, et al
   Coronary Artery Calcification on Low-Dose Lung Cancer Screening CT in South Korea: Visual and Artificial Intelligence-Based Assessment and Association With Cardiovascular Events.
   AJR Am J Roentgenol. 2024 Mar 6. doi: 10.2214/AJR.24.30852.
   PubMed         Abstract available
   
   
2. HARDIE RC, Trout AT, Dillman JR, Narayanan BN, et al
   Performance Analysis in Children of Traditional and Deep-Learning CT Lung Nodule Computer-Aided Detection Systems Trained on Adults.
   AJR Am J Roentgenol. 2023 Nov 22. doi: 10.2214/AJR.23.30345.
   PubMed         Abstract available
   
   
3. PARK J, Lee JH, Hong W, Hwang EJ, et al
   Usual Interstitial Pneumonia: Associations With Complications After Percutaneous Transthoracic Needle Lung Biopsy.
   AJR Am J Roentgenol. 2024;222:e2329938.
   PubMed         Abstract available
   
   

   
   Am J Ind Med

4. MARKOWITZ S, Ringen K, Dement JM, Straif K, et al
   Occupational lung cancer screening: A Collegium Ramazzini statement.
   Am J Ind Med. 2024 Mar 5. doi: 10.1002/ajim.23572.
   PubMed        
   
   

   
   Ann Surg Oncol

5. SARVESTANI AL, Lambdin J, Hu M, Cabanillas M, et al
   Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancers.
   Ann Surg Oncol. 2024;31:2202-2203.
   PubMed        
   
   
6. CHATTERJEE A, Kusamura S, Baratti D, Guaglio M, et al
   ASO Author Reflections: Perioperative Systemic Chemotherapy in Diffuse Malignant Peritoneal Mesothelioma treated with CRS-HIPEC.
   Ann Surg Oncol. 2024;31:2511-2512.
   PubMed        
   
   
7. SHIKANAI S, Yamada N, Yanagawa N, Sugai M, et al
   ASO Visual Abstract: Prognostic Impact of Tumor-Associated Macrophage-Related Markers in Patients with Adenocarcinoma of the Lung.
   Ann Surg Oncol. 2024;31:2521-2522.
   PubMed        
   
   

   
   Anticancer Res

8. YOSHIDA C, Kadota K, Ibuki E, Ishikawa R, et al
   Siglec10 Expression on Tumor-associated Macrophages Is an Independent Prognostic Factor in Stage I Lung Adenocarcinoma.
   Anticancer Res. 2024;44:1289-1297.
   PubMed         Abstract available
   
   

   
   BMC Cancer

9. WANG Y, Ouyang S, Liu M, Si Q, et al
   Humoral immune response to tumor-associated antigen Ubiquilin 1 (UBQLN1) and its tumor-promoting potential in lung cancer.
   BMC Cancer. 2024;24:283.
   PubMed         Abstract available
   
   
10. ZHOU J, Yu B, Guo P, Wang S, et al
    The insufficiency of CT examination in early detection of central lung squamous cell carcinoma and squamous epithelial precancerous lesions.
    BMC Cancer. 2024;24:299.
    PubMed         Abstract available
    
    
11. CHENG M, Shao Y, Li L, Jiang M, et al
    Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review.
    BMC Cancer. 2024;24:312.
    PubMed         Abstract available
    
    
12. WU C, Cao B, He G, Li Y, et al
    Stereotactic ablative brachytherapy versus percutaneous microwave ablation for early-stage non-small cell lung cancer: a multicenter retrospective study.
    BMC Cancer. 2024;24:304.
    PubMed         Abstract available
    
    
13. LIU J, Bian T, She B, Liu L, et al
    Evaluating the comprehensive diagnosis efficiency of lung cancer, including measurement of SHOX2 and RASSF1A gene methylation.
    BMC Cancer. 2024;24:282.
    PubMed         Abstract available
    
    

    
    Br J Cancer

14. FU X, Liu S, Cao D, Li C, et al
    Med23 deficiency reprograms the tumor microenvironment to promote lung tumorigenesis.
    Br J Cancer. 2024;130:716-727.
    PubMed         Abstract available
    
    
15. BLANCO E, Silva-Pilipich N, Bocanegra A, Chocarro L, et al
    Oleuropein-driven reprogramming of the myeloid cell compartment to sensitise tumours to PD-1/PD-L1 blockade strategies.
    Br J Cancer. 2024;130:869-879.
    PubMed         Abstract available
    
    

    
    Cancer Lett

16. ZHANG E, Sun Q, Zhang C, Ma H, et al
    Comprehensive functional interrogation of susceptibility loci in GWASs identified KIAA0391 as a novel oncogenic driver via regulating pyroptosis in NSCLC.
    Cancer Lett. 2024;585:216646.
    PubMed         Abstract available
    
    

    
    Cancer Res

17. WANG H, Zhang Y, Tian Y, Yang W, et al
    DNA-PK-Mediated Cytoplasmic DNA Sensing Stimulates Glycolysis to Promote Lung Squamous Cell Carcinoma Malignancy and Chemoresistance.
    Cancer Res. 2024;84:688-702.
    PubMed         Abstract available
    
    

    
    Cancer Sci

18. ISHIDA M, Iwasaku M, Doi T, Ishikawa T, et al
    Nationwide data from comprehensive genomic profiling assays for detecting driver oncogenes in non-small cell lung cancer.
    Cancer Sci. 2024 Mar 7. doi: 10.1111/cas.16130.
    PubMed         Abstract available
    
    
19. WANG S, Wang J, Gong W, Zhang F, et al
    ILT4 facilitates angiogenesis in non-small cell lung cancer.
    Cancer Sci. 2024 Mar 3. doi: 10.1111/cas.16126.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

20. PONVILAWAN B, Mahadevia H, Qasim H, Sharma P, et al
    Brief Report: Evaluating the Impact of Perioperative Immune Checkpoint Inhibitor in the Treatment of Patients with Resectable Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Clin Lung Cancer. 2024 Feb 15:S1525-7304(24)00014.
    PubMed        
    
    
21. TSUBOKAWA N, Mimae T, Mimura T, Kamigaichi A, et al
    Clinical Significance of Preserving Pulmonary Function After Lung Resection in Early-Stage Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2024 Jan 26:S1525-7304(24)00005.
    PubMed         Abstract available
    
    
22. FIROZ WA, Sen F, Kiuru M, Huang V, et al
    A Case of ROS1-Fusion Non-Small Cell Lung Cancer with Acquired BRAF Mutation Developing Unusual Skin Metastasis.
    Clin Lung Cancer. 2024 Jan 30:S1525-7304(24)00011.
    PubMed        
    
    

    
    Clin Nucl Med

23. LI X, Tian B, Bai X
    FDG PET/CT Findings of a Small Cell Carcinoma of the Lung Presented as Diffuse Dermatomyositis.
    Clin Nucl Med. 2024;49:379-380.
    PubMed         Abstract available
    
    
24. KALANTARI F, Schweighofer-Zwink G, Rendl G, Pirich C, et al
    18F-FDG and 68Ga-PSMA PET/CT in Paratesticular Mesothelioma.
    Clin Nucl Med. 2024;49:332.
    PubMed         Abstract available
    
    
25. TIAN T, Xie H, Huang M
    Epithelial Malignant Pleural Mesothelioma Mimics Lymphoma on 18F-FDG PET/MRI: A Case Report.
    Clin Nucl Med. 2024 Feb 7. doi: 10.1097/RLU.0000000000005095.
    PubMed         Abstract available
    
    
26. SINGH P, Parida GK, Singhal T, Gupta J, et al
    Incidental Detection of Myocardial Ischemia on Whole-Body PET/CT in a Patient With Carcinoma Lung.
    Clin Nucl Med. 2024 Feb 6. doi: 10.1097/RLU.0000000000005082.
    PubMed         Abstract available
    
    
27. BOURBONNE V, Dissaux B, Seizeur R, Nguyen J, et al
    Mismatch Between Brain MRIs and 18F-DOPA PET/CT: Impact on the Management of a Long Survivor With EGFR-Mutated Lung Adenocarcinoma.
    Clin Nucl Med. 2024 Feb 12. doi: 10.1097/RLU.0000000000005058.
    PubMed         Abstract available
    
    
28. JALEEL J, Damle NA, Khurana A, Joshi M, et al
    Pulmonary Mucoepidermoid Carcinoma Mimicking Carcinoid Lung on 18F-FDG and 68Ga-DOTANOC PET/CT.
    Clin Nucl Med. 2024 Feb 2. doi: 10.1097/RLU.0000000000005107.
    PubMed         Abstract available
    
    

    
    Eur J Cardiothorac Surg

29. SINGH A, Mazzola E, Xie Y, Marshall MB, et al
    Lung cancer outcomes in the elderly: Potential disparity in screening.
    Eur J Cardiothorac Surg. 2024 Mar 5:ezae080. doi: 10.1093.
    PubMed         Abstract available
    
    
30. BONGIOLATTI S, Gonfiotti A, Salvicchi A, Voltolini L, et al
    The role of minimally invasive surgery on cT4 tumours: still many unanswered question.
    Eur J Cardiothorac Surg. 2024;65:ezae049.
    PubMed        
    
    

    
    Eur Respir J

31. YOON HY, Kim SY, Song JW
    Association Between High Levels of Nitrogen Dioxide and Increased Cumulative Incidence of Lung Cancer in Patients with Idiopathic Pulmonary Fibrosis.
    Eur Respir J. 2024 Mar 7:2301181. doi: 10.1183/13993003.01181-2023.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

32. YAN W, Ren Z, Chen X, Zhang R, et al
    Potential role of lymphocyte CD44 in determining treatment selection between stereotactic body radiotherapy and surgery for early-stage non-small-cell lung cancer.
    Int J Radiat Oncol Biol Phys. 2024 Mar 4:S0360-3016(24)00356.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

33. MA M, Luo M, Liu Q, Zhong D, et al
    Influence of abdominal fat distribution and inflammatory status on post-operative prognosis in non-small cell lung cancer patients: a retrospective cohort study.
    J Cancer Res Clin Oncol. 2024;150:111.
    PubMed         Abstract available
    
    

    
    J Clin Invest

34. CHEN Z, Vallega KA, Wang D, Quan Z, et al
    DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models.
    J Clin Invest. 2024 Mar 7:e172716. doi: 10.1172/JCI172716.
    PubMed         Abstract available
    
    

    
    J Nucl Med

35. CUZZANI G, Fortunati E, Zanoni L, Nanni C, et al
    Case Report: Pulmonary Actinomyces Infection Mimics Lung Cancer on [(68)Ga]Ga-FAPI PET/CT.
    J Nucl Med. 2024 Mar 7:jnumed.123.267155. doi: 10.2967/jnumed.123.267155.
    PubMed        
    
    
36. HOVHANNISYAN-BAGHDASARIAN N, Luporsi M, Captier N, Nioche C, et al
    Promising Candidate Prognostic Biomarkers in [(18)F]FDG PET Images: Evaluation in Independent Cohorts of Non-Small Cell Lung Cancer Patients.
    J Nucl Med. 2024 Mar 7:jnumed.123.266331. doi: 10.2967/jnumed.123.266331.
    PubMed         Abstract available
    
    
37. LI C, Chen Q, Tian Y, Chen J, et al
    (68)Ga-FAPI-04 PET/CT in Non-Small Cell Lung Cancer: Accurate Evaluation of Lymph Node Metastasis and Correlation with Fibroblast Activation Protein Expression.
    J Nucl Med. 2024 Mar 7:jnumed.123.266806. doi: 10.2967/jnumed.123.266806.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

38. SAIKIA J, Malik PS, Kumar S, Jain D, et al
    Can cell-free DNA (cfDNA) in pleural lavage serve as a predictive and prognostic biomarker among surgically treated Stage I-III a nonsmall cell lung cancer (NSCLC)? A pilot study.
    J Surg Oncol. 2024 Mar 4. doi: 10.1002/jso.27610.
    PubMed         Abstract available
    
    

    
    J Thorac Cardiovasc Surg

39. KRISTENSON K, Hedman K
    Percent predicted peak oxygen uptake is superior to weight-indexed peak oxygen uptake in risk stratification before lung cancer lobectomy.
    J Thorac Cardiovasc Surg. 2024 Mar 5:S0022-5223(24)00187.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

40. WERNER RS, Curioni-Fontecedro A, Mauti LA, Addeo A, et al
    Lung Cancer in Switzerland.
    J Thorac Oncol. 2024;19:385-394.
    PubMed        
    
    
41. TEN HAAF K
    Considerations for Enhancing Lung Cancer Risk Prediction and Screening in Asian Populations.
    J Thorac Oncol. 2024;19:373-375.
    PubMed        
    
    
42. RAMI-PORTA R, Nishimura KK, Giroux DJ, Detterbeck F, et al
    The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer.
    J Thorac Oncol. 2024 Mar 4:S1556-0864(24)00079.
    PubMed         Abstract available
    
    
43. KIM BG, Yoon S, Lee SY, Sohn JW, et al
    How Does Rheumatoid Arthritis Increase the Risk of Lung Cancer?
    J Thorac Oncol. 2024;19:509-510.
    PubMed        
    
    

    
    JAMA Oncol

44. TSUKITA Y, Tozuka T, Kushiro K, Hosokawa S, et al
    Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non-Small Cell Lung Cancer.
    JAMA Oncol. 2024 Mar 7. doi: 10.1001/jamaoncol.2023.6277.
    PubMed         Abstract available
    
    
45. PALMA DA, Bahig H, Hope A, Harrow S, et al
    Stereotactic Radiation Therapy in Early Non-Small Cell Lung Cancer and Interstitial Lung Disease: A Nonrandomized Clinical Trial.
    JAMA Oncol. 2024 Mar 7. doi: 10.1001/jamaoncol.2023.7269.
    PubMed         Abstract available
    
    

    
    Lancet

46. EDERHY S, Cadranel J, Granger C, Hammoudi N, et al
    Investigation of endocarditis finds advanced lung adenocarcinoma: both resolve after tyrosine kinase inhibitor treatment.
    Lancet. 2024;403:860-861.
    PubMed        
    
    

    
    Lung Cancer

47. CONNOR WELLS J, Mullin MM, Ho C, Melosky B, et al
    Outcomes of patients with advanced epithelial growth factor receptor mutant lung cancer treated with first-line osimertinib who would not have met the eligibility criteria for the FLAURA clinical trial.
    Lung Cancer. 2024;190:107529.
    PubMed         Abstract available
    
    
48. SAEKI Y, Maki N, Nemoto T, Inada K, et al
    Lung cancer detection in perioperative patients' exhaled breath with nanomechanical sensor array.
    Lung Cancer. 2024;190:107514.
    PubMed         Abstract available
    
    
49. GOULIAEV A, Ali F, Jakobsen E, Dalton SO, et al
    The Danish lung cancer registry: A nationwide validation study.
    Lung Cancer. 2024;190:107527.
    PubMed         Abstract available
    
    
50. CHUL CHO B, Han JY, Hyeong Lee K, Lee YG, et al
    Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201.
    Lung Cancer. 2024;190:107509.
    PubMed         Abstract available
    
    
51. BAPTISTE OUDART J, Garinet S, Leger C, Barlesi F, et al
    STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial.
    Lung Cancer. 2024;190:107508.
    PubMed         Abstract available
    
    
52. KRAUS KM, Oreshko M, Schnabel JA, Bernhardt D, et al
    Dosiomics and radiomics-based prediction of pneumonitis after radiotherapy and immune checkpoint inhibition: The relevance of fractionation.
    Lung Cancer. 2024;189:107507.
    PubMed         Abstract available
    
    
53. KAIRA K, Imai H, Kagamu H
    Drastic response of sunitinib after failure of Lenvatinib in patients with previously treated thymic carcinoma.
    Lung Cancer. 2024;189:107501.
    PubMed        
    
    
54. ZHOU P, Fu Y, Tang Y, Jiang L, et al
    Thoracic SMARCA4-deficient undifferentiated tumor: A clinicopathological and prognostic analysis of 35 cases and immunotherapy efficacy.
    Lung Cancer. 2024;189:107471.
    PubMed         Abstract available
    
    
55. MOLINA TJ, Roden AC, Szolkowska M, Shimizu S, et al
    International reproducibility study of thymic epithelial tumors staging: pT stage is an issue. proposals for improvement. A RYTHMIC/ITMIG study.
    Lung Cancer. 2024;189:107479.
    PubMed         Abstract available
    
    
56. KLOKER LD, Sidiras M, Flaadt T, Brecht IB, et al
    Clinical management of NUT carcinoma (NC) in Germany: Analysis of survival, therapy response, tumor markers and tumor genome sequencing in 35 adult patients.
    Lung Cancer. 2024;189:107496.
    PubMed         Abstract available
    
    
57. FITZGERALD SM
    Resolving asbestos and ultrafine particulate definitions with carcinogenicity.
    Lung Cancer. 2024;189:107478.
    PubMed         Abstract available
    
    
58. STARES M, Doyle E, Chapple S, Raynes G, et al
    Prognostic value of the Scottish Inflammatory prognostic Score in patients with NSCLC expressing PD-L1 >/= 50 % progressing on first-line pembrolizumab.
    Lung Cancer. 2024;189:107497.
    PubMed         Abstract available
    
    
59. CHEN Y, Chen H, Yu R, Zeng X, et al
    Pulmonary blastoma is successfully treated with immunotherapy and targeted therapy.
    Lung Cancer. 2024;189:107476.
    PubMed         Abstract available
    
    

    
    Mol Cancer Ther

60. MCCRURY M, Swafford K, Shuttleworth SL, Mehdi SH, et al
    Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma.
    Mol Cancer Ther. 2024;23:316-329.
    PubMed         Abstract available
    
    

    
    Oncogene

61. GUO J, Kim D, Gao J, Kurtyka C, et al
    Retraction Note: IKBKE is induced by STAT3 and tobacco carcinogen and determines chemosensitivity in non-small cell lung cancer.
    Oncogene. 2024 Mar 5. doi: 10.1038/s41388-024-02993.
    PubMed        
    
    
62. XU X, Qiu S, Zeng B, Huang Y, et al
    N(6)-methyladenosine demethyltransferase FTO mediated m(6)A modification of estrogen receptor alpha in non-small cell lung cancer tumorigenesis.
    Oncogene. 2024 Mar 5. doi: 10.1038/s41388-024-02992.
    PubMed         Abstract available
    
    

    
    Oncologist

63. XU Y, Wen N, Haddad RI, Sonis ST, et al
    Comparisons of Non-Oral Immune-Related Adverse Events Among Patients With Cancer With Different Oral Toxicity Profiles.
    Oncologist. 2024;29:e382-e391.
    PubMed         Abstract available
    
    

    
    PLoS One

64. AJENU EO, Seideneck AM, Pandellapalli E, Shinsky EM, et al
    ABCG2 transporter reduces protein aggregation in cigarette smoke condensate-exposed A549 lung cancer cells.
    PLoS One. 2024;19:e0297661.
    PubMed         Abstract available
    
    
65. KESSLER LG, Comstock B, Aiello Bowles EJ, Mou J, et al
    Protocol to measure validity and reliability of colorectal, breast, cervical and lung cancer screening questions from the 2021 National Health Interview Survey: Methodology and design.
    PLoS One. 2024;19:e0297773.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.